Dumac Inc. Lowers Stake in UiPath Inc. (NASDAQ:PATH)

Dumac Inc. lessened its stake in UiPath Inc. (NASDAQ:PATHGet Rating) by 18.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 16,332 shares of the healthcare company’s stock after selling 3,647 shares during the quarter. UiPath makes up approximately 2.2% of Dumac Inc.’s portfolio, making the stock its 8th biggest holding. Dumac Inc.’s holdings in UiPath were worth $704,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of PATH. Deutsche Bank AG raised its holdings in shares of UiPath by 18.4% in the 3rd quarter. Deutsche Bank AG now owns 4,153 shares of the healthcare company’s stock worth $218,000 after purchasing an additional 645 shares during the period. BlackRock Inc. grew its stake in UiPath by 263.7% in the 3rd quarter. BlackRock Inc. now owns 3,707,337 shares of the healthcare company’s stock valued at $195,043,000 after buying an additional 2,687,909 shares in the last quarter. Creative Planning grew its stake in UiPath by 45.9% in the 3rd quarter. Creative Planning now owns 6,258 shares of the healthcare company’s stock valued at $329,000 after buying an additional 1,969 shares in the last quarter. US Bancorp DE grew its stake in UiPath by 3,959.2% in the 3rd quarter. US Bancorp DE now owns 32,961 shares of the healthcare company’s stock valued at $1,735,000 after buying an additional 32,149 shares in the last quarter. Finally, First Republic Investment Management Inc. purchased a new position in UiPath in the 3rd quarter valued at approximately $1,393,000. 52.19% of the stock is currently owned by institutional investors.

In other news, Director Kimberly Hammonds sold 2,521 shares of the company’s stock in a transaction dated Friday, March 18th. The shares were sold at an average price of $28.19, for a total transaction of $71,066.99. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 31.88% of the company’s stock.

Shares of NASDAQ:PATH traded down $0.04 during midday trading on Friday, hitting $17.94. 425,582 shares of the stock traded hands, compared to its average volume of 6,471,258. The stock has a market capitalization of $9.73 billion and a PE ratio of -10.90. The business’s 50 day moving average is $20.54 and its two-hundred day moving average is $33.17. UiPath Inc. has a one year low of $13.66 and a one year high of $90.00.

UiPath (NASDAQ:PATHGet Rating) last issued its quarterly earnings data on Wednesday, March 30th. The healthcare company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.08). The firm had revenue of $289.70 million for the quarter, compared to the consensus estimate of $283.25 million. UiPath had a negative net margin of 58.91% and a negative return on equity of 21.20%. The firm’s revenue for the quarter was up 39.3% compared to the same quarter last year. Sell-side analysts expect that UiPath Inc. will post -0.46 earnings per share for the current year.

PATH has been the subject of a number of recent analyst reports. Truist Financial reduced their price target on shares of UiPath from $75.00 to $55.00 and set a “buy” rating for the company in a research report on Thursday, March 31st. Cowen reduced their price target on shares of UiPath from $43.00 to $27.00 in a research report on Friday. Zacks Investment Research lowered shares of UiPath from a “hold” rating to a “strong sell” rating in a research report on Thursday, April 7th. Canaccord Genuity Group reduced their price target on shares of UiPath from $55.00 to $30.00 in a research report on Thursday, March 31st. Finally, Mizuho reduced their price target on shares of UiPath from $70.00 to $40.00 and set a “buy” rating for the company in a research report on Thursday, March 31st. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and twelve have given a buy rating to the company. According to MarketBeat, UiPath currently has an average rating of “Hold” and an average price target of $39.98.

About UiPath (Get Rating)

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.

Featured Stories

Want to see what other hedge funds are holding PATH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for UiPath Inc. (NASDAQ:PATHGet Rating).

Institutional Ownership by Quarter for UiPath (NASDAQ:PATH)

Receive News & Ratings for UiPath Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UiPath and related companies with MarketBeat.com's FREE daily email newsletter.